October 8, 2019

New treatment approved for wet age-related macular degeneration

by

New treatment approved for wet age-related macular degeneration

Novartis announced on October 8, 2019 that the US Food and Drug Administration (FDA) approved BEOVU® (brolucizumab-dbll) injection for the treatment of wet age-related macular degeneration (wet AMD). This is the fourth anti-VEGF drug treatment to be approved for wet AMD, the others being Lucentis (Genentech), Eylea (Regeneron), and off-label Avastin (Genentech). Similar to its predecessors, BEOVU® carries a recommended dosing schedule of monthly for the first three doses followed by one dose every 8-12 weeks. This approval now provides more options for doctors and patients.

SOURCE: Novartis press release

For descriptions of this and other anti-VEGF treatments for wet AMD now in clinical use and in trials, see Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration

We offer resources and free materials for those living with low vision.

View Resources